ALK+ anaplastic large cell lymphoma
Conditions
Interventions
Control group:Etoposide 60mg/m2/d d1-4
Methylprednisolone 500mg/d d1-4
Cytarabine 2g/m2/Q12h d5
Cisplatin 25mg/m2/d d1-4
Experimental group:Etoposide 60mg/m2/d d1-4
ATO 10mg/d d1-14
Sponsors
Tongji Hospital Affiliated to Tongji University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-70 years; 2. Diagnosed with histologically confirmed ALK positive anaplastic large lymphoma (WHO classification(2016)); 3. Didn't reach CR or relapsed following first-line treatment; 4. Measurable disease with baseline positron emission tomography (PET) scans demonstrating positive lesions compatible with anatomical tumour sites identified by computerized tomography (CT); 5. Patients were required to have an Eastern Cooperative Oncology Group performance status of 0-2.
Exclusion criteria
Exclusion criteria: 1. Pregnant or nursing women; 2. Human infected immunodeficiency virus,active hepatitis B or C; 3. Presence of central nervous involvement; 4. History of myocardial infarction within the past 6 months; 5. Any significant concurrent,uncontrolled medical condition; 6. Total bilirubin >2x upper limit of normal (ULN),and/or alkaline phosphatase or aspartate aminotrnaferase >2.5x ULN unless there was evidence of direct liver involvemet by lymphoma; 7. Creatinine >1.5x ULN; 8. Any other tumour.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| CR;PR;OS;PFS;AE; | — |
Countries
China
Contacts
Public ContactDing Yi
Tongji Hospital Affiliated to Tongji University School of Medicine
Outcome results
None listed